Loading...
XHKG6185
Market cap1.28bUSD
Dec 27, Last price  
29.55HKD
1D
-0.66%
1Q
42.22%
IPO
-12.86%
Name

CanSino Biologics Inc

Chart & Performance

D1W1MN
XHKG:6185 chart
P/E
—
P/S
26.43
EPS
—
Div Yield, %
0.04%
Shrs. gr., 5y
2.49%
Rev. gr., 5y
213.94%
Revenues
345m
-66.52%
8,195,0009,182,0001,132,0002,283,39118,544,0004,299,702,0001,031,041,000345,182,000
Net income
-1.48b
L+53.69%
-49,851,000-64,450,000-138,281,000-153,109,000-358,490,0001,914,390,000-964,757,000-1,482,732,000
CFO
-908m
L-51.88%
-34,383,000-56,301,000-123,638,000-170,189,000-469,389,0002,014,557,000-1,887,599,000-908,227,507
Dividend
Jul 13, 20220.93727 HKD/sh

Profile

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.
URL
http://www.cansinotech.com/
IPO date
Mar 28, 2019
Employees
2,291
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
345,182
-66.52%
1,031,041
-76.02%
4,299,702
23,086.49%
Cost of revenue
2,507,036
2,540,585
2,512,835
Unusual Expense (Income)
NOPBT
(2,161,854)
(1,509,544)
1,786,867
NOPBT Margin
41.56%
Operating Taxes
(11,451)
(219,244)
29,701
Tax Rate
1.66%
NOPAT
(2,150,402)
(1,290,300)
1,757,166
Net income
(1,482,732)
53.69%
(964,757)
-150.40%
1,914,390
-634.01%
Dividends
(3,628)
(193,932)
(14,098)
Dividend yield
0.06%
1.18%
0.03%
Proceeds from repurchase of equity
(150,169)
BB yield
0.91%
Debt
Debt current
1,459,498
1,624,335
1,111,969
Long-term debt
1,480,659
1,323,340
516,876
Deferred revenue
204,998
187,955
Other long-term liabilities
225,209
(878,008)
Net debt
446,603
(497,264)
(3,873,338)
Cash flow
Cash from operating activities
(908,228)
(1,887,599)
2,014,557
CAPEX
(610,470)
(1,075,013)
(1,203,136)
Cash from investing activities
(449,646)
(1,191,955)
(2,531,270)
Cash from financing activities
(7,582)
854,602
1,559,922
FCF
840,114
(3,496,220)
(576,357)
Balance
Cash
4,119,965
5,946,791
7,782,906
Long term investments
(1,626,411)
(2,501,852)
(2,280,723)
Excess cash
2,476,295
3,393,387
5,287,198
Stockholders' equity
(1,298,153)
669,401
1,831,597
Invested Capital
9,484,576
8,580,102
8,244,525
ROIC
23.34%
ROCE
17.73%
EV
Common stock shares outstanding
246,766
247,022
247,450
Price
23.55
-64.72%
66.75
-62.96%
180.20
4.65%
Market cap
5,811,339
-64.76%
16,488,718
-63.02%
44,590,489
12.14%
EV
6,270,930
16,488,966
41,269,989
EBITDA
(1,892,800)
(1,313,184)
1,875,409
EV/EBITDA
22.01
Interest
64,145
41,341
20,419
Interest/NOPBT
1.14%